Abstract 7770: Comparative Effectiveness of Direct Oral Anticoagulants in Preventing Post-Thrombotic Syndrome After Acute Deep Vein Thrombosis
Abstract
Background: Post-thrombotic syndrome (PTS) is a common chronic complication following acute deep vein thrombosis (DVT), affecting up to 20-50% of patients and leading to impaired quality of life and increased healthcare utilization. While direct oral anticoagulants (DOACs) are widely used for venous thromboembolism treatment, comparative data regarding their effectiveness in preventing PTS remain limited. We compared the incidence of PTS among patients treated with rivaroxaban versus apixaban following acute DVT. Methods: We conducted a real-world retrospective cohort study using the TriNetX Global Collaborative Network, including adult patients diagnosed with acute lower extremity DVT between January 1, 2015, and December 31, 2025. Patients received either rivaroxaban or apixaban within 6 months of DVT diagnosis. PTS was identified using ICD-10 diagnostic codes. Patients with malignancy, antiphospholipid syndrome, mechanical heart valves, dialysis dependence, or end-stage renal disease were excluded. Propensity score matching (1:1) was performed to balance demographics, comorbidities, medications, and laboratory values, yielding 2,666 patients in each cohort. The primary outcome was development of PTS between 180 and 730 days after index DVT. Secondary outcomes included recurrent venous thromboembolism (VTE), bleeding, and all-cause mortality. Results: After propensity matching, baseline characteristics were well balanced between cohorts. Patients treated with rivaroxaban demonstrated a significantly lower incidence of PTS compared with apixaban (0.6% [n=16] vs 1.3% [n=35]; risk ratio [RR] 0.50, 95% CI 0.28-0.89; p=0.017). Kaplan-Meier analysis showed higher PTS-free survival with rivaroxaban (99.28% vs 98.34%; log-rank p=0.004), with a hazard ratio (HR) of 0.44 (95% CI 0.24-0.78). Rates of recurrent VTE were numerically higher in the rivaroxaban cohort (29.9% vs 24.9%; RR 1.20, 95% CI 1.10-1.31), although time-to-event analysis did not demonstrate a significant difference (HR 1.08, 95% CI 0.97-1.19; p=0.168). No significant difference in bleeding or all-cause mortality was observed. Conclusion: In this large real-world propensity-matched analysis, rivaroxaban was associated with a significantly lower risk of post-thrombotic syndrome compared with apixaban following acute DVT. These findings suggest potential differences among DOACs in long-term venous outcomes and warrant further prospective investigation to guide optimal anticoagulant selection for PTS prevention.